Skip to content

Neuroprotective potential of chrysin against ketamine-induced neurotoxicity: Effects on behavioral changes, oxidative stress, and neuroinflammation.

Onur Karaca, Özge Kandemir, Hasan Şimşek, Nurhan Akaras, Şeyda Öte Karaca, Fatih Mehmet Kandemir

Neurotoxicology and Teratology September 18, 2026 DOI: 10.1016/j.ntt.2026.107720 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Controlled experimental animal study Peer reviewed
Sample size 35
Population Adult male Wistar rats
Interventions Ketamine Chrysin
Dose Ketamine 30 mg/kg i.p.; Chrysin 25 or 50 mg/kg p.o.
Duration 10-day treatment regimen
Measures Morris Water Maze test, MDA, GSH, SOD, CAT, GPx, NF-κB, TNF-α, iNOS, Bax, Caspase-3, Bcl-2, CaMKII, GFAP
Topics Ketamine Esketamine
Keywords Oxidative stress Neurotoxicity Neuroinflammation Chrysin
Key findings Ketamine given for 10 days increased oxidative stress, neuroinflammation, and apoptotic markers and produced neuronal degeneration, necrosis, and vascular hyperemia in rat cerebral cortex and hippocampus. Chrysin, particularly at 50 mg/kg, reduced these histopathological changes and lowered GFAP and Caspase-3 expression, suggesting it may be a promising adjunctive neuroprotective agent.

Abstract

Aim: Ketamine (KTM) is widely used in clinical settings for its anesthetic, analgesic, and antidepressant properties. However, prolonged or repeated KTM exposure can induce neurotoxicity through oxidative stress, neuroinflammation, and apoptotic mechanisms. This study investigated the neuroprotective effects of Chrysin (CHR), a natural flavonoid with potent antioxidant and anti-inflammatory properties, against KTM-induced neurotoxicity in rats.

Methods: Adult male Wistar rats were divided into five groups (n = 7): Control, KTM, CHR KTM + CHR25 and KTM + CHR50. Following a 10-day treatment regimen (KTM:30 mg/kg, i.p.; CHR: 25 or 50 mg/kg, p.o.) cognitive function was assessed using the Morris Water Maze test.

Results: Biochemical analyses revealed that KTM significantly increased MDA levels while decreasing GSH levels and antioxidant enzyme (SOD,CAT,GPx) activities in brain and hippocampus tissues. KTM also upregulated pro-inflammatory (NF-κB,TNF-α,iNOS) and pro-apoptotic (Bax,Caspase-3) markers while downregulating anti-apoptotic Bcl-2 and CaMKII isoforms. Histopathological examination showed that KTM induced neuronal degeneration, necrosis, and vascular hyperemia in cerebral cortex and hippocampus, while immunohistochemical analysis revealed increased GFAP and Caspase-3 immunopositivity. CHR treatment, particularly at the higher dose, significantly ameliorated these histopathological alterations and reduced GFAP and Caspase-3 expression.

Conclusion: These findings suggest that CHR represents a promising adjunctive neuroprotective agent that could mitigate KTM-associated neurotoxicity while preserving its therapeutic applications.

In the evidence

This study is part of the evidence base for a synthesis in the library. Here is how each one recorded it.

  • Chrysin appeared to protect against ketamine-induced neurotoxicity by reducing behavioral changes, oxidative stress, and neuroinflammation.

    Synthesized

Comparable studies

Other preclinical and animal studies on ketamine, most cited first.

Explore topics